DLBCL

Early Rituximab Intensification Generates No Differences in Outcomes as Treatment of DLBCL

August 04, 2020

Early rituximab intensification during treatment with R-CHOP demonstrated no difference in outcomes as treatment of patients with diffuse large B-cell lymphoma.

Salvage Blinatumomab Therapy Generates Durable Responses in Relapsed/Refractory DLBCL

August 03, 2020

Blinatumomab as salvage therapy for patients with relapsed/refractory diffuse large B-cell lymphoma may induce durable complete responses and a survival benefit, according to a pooled analysis of 3 clinical trials.

FDA Approves Tafasitamab/Lenalidomide for R/R DLBCL

August 01, 2020

The FDA has approved tafasitamab-cxix in combination with lenalidomide for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma not otherwise specific, including DLBCL arising from low-grade lymphoma, and patients who are not eligible for autologous stem cell transplant.

Selinexor Introduces a New Mechanism of Action to Treat Relapsed or Refractory DLBCL

June 22, 2020

In an interview with Targeted Oncology, Michael Schuster, MD, discussed the findings in the phase 2 SADAL study and the importance of the FDA approval of selinexor for the treatment of relapsed/refractory diffuse large B-cell lymphoma.

FDA Approves Selinexor for R/R Diffuse Large B-Cell Lymphoma

June 22, 2020

Selinexor is now the only single-agent, oral therapy approved for the treatment of patients with R/R DLBCL, and the only nuclear export inhibitor approved by the FDA for use in 2 hematologic malignancies, multiple myeloma and DLBCL.

Tafasitamab Plus Lenalidomide Demonstrates Long-Term Efficacy in R/R DLBCL

June 15, 2020

“These results, complimented with a favorable safety profile, indicate the utility of this novel immunological combination as a potential treatment option for patients with relapsed or refractory diffuse large B-cell lymphoma."

Better Outcomes Observed With CAR T-Cell Therapy in Younger Patients With R/R DLBCL

June 06, 2020

Chimeric antigen receptor T-cell therapy lead to poor overall survival outcomes it patients who were 75 years or older with relapsed/refractory diffuse large B-cell lymphoma compared with patients aged 70 to 74 years, but progression-free survival was comparable between the 2 groups.

Targeting CD19 in Diffuse Large B-Cell Lymphoma

May 07, 2020

Experts in the management of diffuse large B-cell lymphoma (DLBCL) discuss the use of novel CD19-antibody mono- and combination therapies to treat relapsed/refractory subpopulations.

Avadomide Demonstrates Preliminary Activity in Diffuse Large B-cell Lymphoma

May 05, 2020

A safety, tolerability, pharmacokinetics, and preliminary efficacy of avadomide in patients with advanced solid tumors, non-Hodgkin lymphomas, or multiple myeloma shows evidence of preliminary activity. Findings from the diffuse large B-cell cohort were published in Blood.

CAR T-Cell Therapy Appears Promising in Relapsed/Refractory DLBCL

April 15, 2020

David Miklos, MD, discusses exciting data for the use of chimeric antigen receptor T-cell therapy as treatment of patients with diffuse large B-cell lymphoma.